UA90657C2 - Ловушки vegf и их терапевтические применения - Google Patents

Ловушки vegf и их терапевтические применения

Info

Publication number
UA90657C2
UA90657C2 UAA200600768A UAA200600768A UA90657C2 UA 90657 C2 UA90657 C2 UA 90657C2 UA A200600768 A UAA200600768 A UA A200600768A UA A200600768 A UAA200600768 A UA A200600768A UA 90657 C2 UA90657 C2 UA 90657C2
Authority
UA
Ukraine
Prior art keywords
vegf
therapeutic uses
vegf traps
traps
tissues
Prior art date
Application number
UAA200600768A
Other languages
English (en)
Ukrainian (uk)
Inventor
Томас Дж. Дейли
Джеймс П. Фенлд
Николас Дж. ПАПАДОПУЛОС
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33552268&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA90657(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of UA90657C2 publication Critical patent/UA90657C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к молекуле нуклеиновой кислоты и слитых белков, способных связывать фактор роста эндотелиальных клеток сосудов VEGF. Также изобретение относится к ловушкам VEGF, которые терапевтически применены для лечения связанных с VEGF состояний или заболеваний и специально сконструированы для локального введения в конкретные органы, ткани и/или клетки.
UAA200600768A 2003-06-30 2004-06-29 Ловушки vegf и их терапевтические применения UA90657C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/609,775 US7087411B2 (en) 1999-06-08 2003-06-30 Fusion protein capable of binding VEGF

Publications (1)

Publication Number Publication Date
UA90657C2 true UA90657C2 (ru) 2010-05-25

Family

ID=33552268

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA200600768A UA90657C2 (ru) 2003-06-30 2004-06-29 Ловушки vegf и их терапевтические применения
UAA201000776A UA105625C2 (ru) 2003-06-30 2004-06-29 Ловушка vegf и ее терапевтическое применение

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA201000776A UA105625C2 (ru) 2003-06-30 2004-06-29 Ловушка vegf и ее терапевтическое применение

Country Status (29)

Country Link
US (4) US7087411B2 (ru)
EP (2) EP1639007B1 (ru)
JP (2) JP2007528708A (ru)
KR (1) KR101131429B1 (ru)
CN (1) CN1816566B (ru)
AR (1) AR044938A1 (ru)
AT (2) ATE427962T1 (ru)
AU (1) AU2004252175B2 (ru)
BR (1) BRPI0412125A (ru)
CA (1) CA2529660C (ru)
CY (2) CY1109204T1 (ru)
DE (2) DE602004029833D1 (ru)
DK (2) DK1947118T3 (ru)
ES (2) ES2323468T3 (ru)
HK (1) HK1082511A1 (ru)
IL (2) IL172404A (ru)
MX (1) MXPA05013641A (ru)
MY (1) MY154826A (ru)
NO (1) NO339766B1 (ru)
NZ (2) NZ572107A (ru)
PL (2) PL1947118T3 (ru)
PT (2) PT1947118E (ru)
RU (1) RU2376373C2 (ru)
SI (2) SI1947118T1 (ru)
TW (1) TWI330197B (ru)
UA (2) UA90657C2 (ru)
UY (1) UY28396A1 (ru)
WO (1) WO2005000895A2 (ru)
ZA (1) ZA200600157B (ru)

Families Citing this family (212)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US20090155266A1 (en) * 2004-01-16 2009-06-18 Yale University Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases
EP1732947B1 (en) * 2004-03-05 2011-04-27 Vegenics Pty Ltd Growth factor binding constructs materials and methods
EP2583685A1 (en) 2004-06-10 2013-04-24 Regeneron Pharmaceuticals, Inc. Method of administering and using VEGF inhibitors for the treatment of human cancer
ATE470454T1 (de) 2004-09-13 2010-06-15 Genzyme Corp Multimere konstrukte
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
WO2006086544A2 (en) * 2005-02-11 2006-08-17 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
CN102614134B (zh) 2005-03-25 2016-09-07 瑞泽恩制药公司 Vegf拮抗剂制剂
CN101237880B (zh) 2005-08-12 2011-09-21 瑞泽恩制药公司 通过vegf拮抗剂的皮下给药治疗疾病
US8329866B2 (en) * 2005-10-03 2012-12-11 Bolder Biotechnology, Inc. Long acting VEGF inhibitors and methods of use
ES2400666T5 (es) * 2005-12-16 2016-03-10 Regeneron Pharmaceuticals, Inc. Uso terapéutico de un antagonista de DII4 y un inhibidor de VEGF para inhibir el crecimiento tumoral
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
US8216575B2 (en) * 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
LT2944306T (lt) 2006-06-16 2021-02-25 Regeneron Pharmaceuticals, Inc. Vfgf antagonisto kompozicijos, tinkamos įvedimui intravitrealiniu būdu
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
AU2007351813B2 (en) 2006-10-31 2013-10-10 East Carolina University Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
MX2009013004A (es) 2007-06-01 2010-01-20 Univ Maryland Agentes de union al receptor de la region constante fc de inmunoglobulina.
TWI436775B (zh) * 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
KR101698362B1 (ko) * 2008-11-03 2017-01-20 몰리큘라 파트너스 아게 Ｖｅｇｆ－ａ 수용체 상호작용을 억제하는 결합 단백질
EP2727996A1 (en) * 2008-11-06 2014-05-07 The Johns-Hopkins University Treatment of chronic inflammatory respiratory disorders with NP1 inhibitors
EP2413958A4 (en) 2009-03-31 2014-04-02 Univ East Carolina CYTOKINES AND NEUROANTIGENES FOR THE TREATMENT OF IMMUNE DISEASES
EP3028707A1 (en) * 2009-05-01 2016-06-08 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
CN103124788B (zh) 2010-05-21 2016-01-13 梅里麦克制药股份有限公司 双特异性融合蛋白
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TWI542597B (zh) 2010-07-28 2016-07-21 吉林尼克公司 產生依序多聚體化免疫球蛋白ｆｃ組合物之天然人類蛋白質片段之融合蛋白
MY160445A (en) 2010-08-03 2017-03-15 Abbvie Inc Dual Variable Domain Immunoglobulins And Uses Thereof
PT2601214T (pt) 2010-08-06 2017-12-20 Genzyme Corp Composições de antagonistas de vegf e utilizações destes
EP2638073A4 (en) * 2010-11-09 2014-05-07 Altimab Therapeutics Inc PROTEIN COMPLEXES FOR ANTIGEN BINDING, AND METHODS OF USE
KR20220097542A (ko) 2011-01-13 2022-07-07 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
ES2664224T3 (es) 2011-08-19 2018-04-18 Children's Medical Center Corporation Proteína de unión a VEGF para el bloqueo de la angiogénesis
AU2012299195B9 (en) 2011-08-19 2018-05-10 Regeneron Pharmaceuticals, Inc Anti-Tie2 antibodies uses thereof
KR20140069331A (ko) 2011-09-30 2014-06-09 리제너론 파아마슈티컬스, 인크. 항-ＥｒｂＢ3 항체 및 이의 용도
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
RU2642664C2 (ru) 2011-11-18 2018-01-25 Ридженерон Фармасьютикалз, Инк. Полимерные белковые микрочастицы
CN110078831A (zh) * 2011-12-01 2019-08-02 圆祥生命科技股份有限公司 补体和vegf途径的蛋白质抑制剂及其使用方法
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
EP2825553B1 (en) 2012-03-14 2018-07-25 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
TWI702955B (zh) 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ）
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
US9683044B2 (en) 2012-08-20 2017-06-20 Gliknik Inc. Molecules with antigen binding and polyvalent FC gamma receptor binding activity
RU2542385C2 (ru) * 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
SG11201502933UA (en) 2012-11-13 2015-05-28 Regeneron Pharma Anti-prokineticin receptor (prokr) antibodies and uses thereof
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
AU2014218318B2 (en) * 2013-02-18 2018-02-15 Vegenics Pty Limited Ligand binding molecules and uses thereof
US10377817B2 (en) 2013-03-14 2019-08-13 Regeneron Pharmaceuticals, Inc. Human antibodies to GREM1
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
EP3019243A4 (en) 2013-07-12 2017-03-15 Ophthotech Corporation Methods for treating or preventing ophthalmological conditions
KR102060187B1 (ko) 2013-07-19 2019-12-27 삼성전자주식회사 Vegf-c, vegf-d 및/또는 안지오포이에틴-2를 동시에 저해하는 융합 폴리펩타이드 및 이의 용도
WO2015058369A1 (en) * 2013-10-23 2015-04-30 Sanofi (China) Investment Co., Ltd. Use of aflibercept and docetaxel for the treatment of nasopharyngeal carcinoma
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JP6632984B2 (ja) 2014-03-11 2020-01-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ＥＧＦＲｖＩＩＩ抗体およびその使用
IL259321B2 (en) 2014-03-17 2023-10-01 Univ Washington Preparations and methods for increasing gene expression in frogs
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EP3170005B1 (en) 2014-07-18 2019-04-10 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
US20170216403A1 (en) 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
DK3180018T3 (da) 2014-08-12 2019-10-28 Massachusetts Inst Technology Synergistisk tumorbehandling med IL-2 og integrinbindende Fc-fusionsprotein
DK3221359T3 (da) 2014-11-17 2020-06-22 Regeneron Pharma Fremgangsmåder til tumorbehandling ved anvendelse af CD3XCD20-bispecifikt antistof
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
AU2016226289B2 (en) 2015-03-02 2021-04-29 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
TW202336236A (zh) 2015-03-27 2023-09-16 美商再生元醫藥公司 偵測生物污染物之組成物及方法
EA034950B1 (ru) 2015-03-27 2020-04-09 Регенерон Фармасьютикалз, Инк. Производные майтанзиноида, их конъюгаты и способы использования
IL285359B2 (en) * 2015-04-23 2024-01-01 Hemanext Inc Anaerobic blood storage containers
CA2984010A1 (en) 2015-05-12 2016-11-17 Regeneron Pharmaceuticals, Inc. Multimeric protein purity determination
RU2612497C2 (ru) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
TWI797060B (zh) * 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
TWI784917B (zh) 2015-09-23 2022-11-21 美商再生元醫藥公司 最優化抗ｃｄ３雙特異性抗體及其用途
WO2017058923A1 (en) 2015-09-28 2017-04-06 East Carolina University Aluminum based adjuvants for tolerogenic vaccination
US10040840B2 (en) 2015-10-02 2018-08-07 Silver Creek Pharmaceuticals, Inc. Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
WO2017070866A1 (zh) * 2015-10-28 2017-05-04 黄志清 一种抗血管内皮生长因子的氧化石墨烯与其用途
CA3005391A1 (en) * 2015-11-19 2017-05-26 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
KR102343004B1 (ko) 2015-12-03 2021-12-24 리제너론 파마슈티칼스 인코포레이티드 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
AU2016366521A1 (en) 2015-12-11 2018-06-21 Regeneron Pharmaceuticals, Inc. Methods for reducing or preventing growth of tumors resistant to EGFR and/or ErbB3 blockade
CN108366968B (zh) 2015-12-16 2022-02-18 瑞泽恩制药公司 制造蛋白质微粒的组合物和方法
BR112018012801B1 (pt) 2015-12-22 2024-03-12 Regeneron Pharmaceuticals, Inc Usos de uma combinação de anticorpos anti-pd-1 e anticorpos biespecíficos anti-cd20/anti-cd3 e de uma composição farmacêutica
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
SG11201806322QA (en) 2016-01-25 2018-08-30 Regeneron Pharma Maytansinoid derivatives, conjugates thereof, and methods of use
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
EP3448437B1 (en) 2016-04-29 2021-12-29 Adverum Biotechnologies, Inc. Evasion of neutralizing antibodies by a recombinant adeno-associated virus
TWI755395B (zh) 2016-05-13 2022-02-21 美商再生元醫藥公司 抗-pd-1抗體與輻射治療癌症之組合
WO2017214321A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
MX2018015350A (es) 2016-06-10 2019-08-26 Regeneron Pharma Anticuerpos anti-gitr y sus usos.
EA038729B1 (ru) 2016-07-29 2021-10-12 Ридженерон Фармасьютикалз, Инк. Сборочная линия со встроенным электронным визуальным контролем
CA3031742A1 (en) 2016-08-16 2018-02-22 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
KR102534506B1 (ko) 2016-08-18 2023-05-30 리제너론 파마슈티칼스 인코포레이티드 농도-의존적 자가-상호작용 나노입자 분광법을 사용하는 단백질의 자가-결합하는 능력을 결정하기 위한 분석
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
EA201990781A9 (ru) 2016-09-23 2019-11-27 Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
BR112019005697A2 (pt) 2016-09-23 2019-07-16 Regeneron Pharma anticorpos anti-muc16-cd3 biespecíficos e conjugados de fármaco e anti-muc16
MY197672A (en) 2016-10-07 2023-07-03 Regeneron Pharma Room temperature stable lyophilized protein
WO2018075798A1 (en) 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
KR20230119729A (ko) 2016-10-25 2023-08-16 리제너론 파아마슈티컬스, 인크. 크로마토그래피 데이터 분석을 위한 방법 및 시스템
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US11135266B2 (en) 2016-11-21 2021-10-05 Just-Evotec Biologics, Inc. Aflibercept formulations and uses thereof
CA3044534A1 (en) 2016-11-29 2018-06-07 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer
CA3043261A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Manufacturing optimization of gl-2045, a multimerizing stradomer
AU2018207303A1 (en) 2017-01-10 2019-07-25 xCella Biosciences, Inc. Combination tumor treatment with an integrin-binding-Fc fusion protein and immune modulator
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
MA46814B2 (fr) 2017-02-10 2022-09-30 Regeneron Pharma Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet
MA47604A (fr) 2017-02-21 2020-01-01 Regeneron Pharma Anticorps anti-pd-1 pour le traitement du cancer du poumon
EP3596213A4 (en) 2017-03-17 2021-02-17 Adverum Biotechnologies, Inc. COMPOSITIONS AND PROCEDURES FOR ENHANCED GENE EXPRESSION
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
AU2018266324B2 (en) 2017-05-06 2024-02-01 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
CA3066779A1 (en) 2017-06-28 2019-01-03 Regeneron Pharmaceuticals, Inc. Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof
US20190010531A1 (en) 2017-07-06 2019-01-10 Regeneron Pharmaceuticals, Inc. Cell culture process for making a glycoprotein
MA49683A (fr) 2017-07-24 2020-06-03 Regeneron Pharma Anticorps anti-cd8 et leurs utilisations
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
CA3185107A1 (en) 2017-10-12 2019-04-18 Immunowake Inc. Vegfr-antibody light chain fusion protein
MX2020003945A (es) * 2017-10-18 2020-11-09 Regenxbio Inc Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente .
CN111465407A (zh) 2017-11-30 2020-07-28 瑞泽恩制药公司 使用vegf拮抗剂治疗生血管性眼病
WO2019118187A1 (en) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Devices and systems for chromatography column bed support management and related methods
WO2019126123A1 (en) 2017-12-22 2019-06-27 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
AU2019212622B2 (en) 2018-01-26 2024-05-23 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
JP7349998B2 (ja) 2018-01-31 2023-09-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド サイズバリアントおよび電荷バリアントである薬物製品不純物を特徴解析するためのシステムおよび方法
TWI825066B (zh) 2018-02-01 2023-12-11 美商再生元醫藥公司 治療性單株抗體之品質屬性的定量及模型化
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
CA3088906A1 (en) 2018-02-28 2019-09-06 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
FI3768709T3 (fi) 2018-03-19 2024-02-01 Regeneron Pharma Mikrosirukapillaarielektroforeesianalyysejä ja -reagensseja
US20210113615A1 (en) 2018-04-13 2021-04-22 Ludwig Institute For Cancer Research Ltd. Heterodimeric inactivatable chimeric antigen receptors
US20210246224A1 (en) 2018-04-30 2021-08-12 Regeneron Pharmaceuticals, Inc. Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof
TW202348297A (zh) 2018-05-02 2023-12-16 美商里珍納龍藥品有限公司 用於評估生化過濾器的適合性的方法
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
MA52570A (fr) 2018-05-10 2021-03-17 Regeneron Pharma Formulations contenant des protéines de fusion du récepteur vegf à haute concentration
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
TW202005985A (zh) 2018-06-21 2020-02-01 美商再生元醫藥公司 用雙特異性抗ＣＤ３ｘＭＵＣ１６抗體及抗ＰＤ－１抗體治療癌症的方法
TW202005694A (zh) 2018-07-02 2020-02-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
CA3106997A1 (en) 2018-08-13 2020-02-20 Regeneron Pharmaceuticals, Inc. Therapeutic protein selection in simulated in vivo conditions
CN112601963B (zh) 2018-08-30 2024-05-24 瑞泽恩制药公司 用于表征蛋白质复合物的方法
MA53981A (fr) 2018-10-23 2021-09-01 Regeneron Pharma Récepteurs de lymphocytes t de ny-eso-1 et leurs procédés d'utilisation
CN113508127A (zh) 2018-11-06 2021-10-15 阿尔萨泰克公司 神经变性疾病的基于细胞的基因疗法
FI3857237T3 (fi) 2019-01-16 2023-05-03 Regeneron Pharma Disulfidisidosten luonnehtimismenetelmiä
JP2022517821A (ja) 2019-01-25 2022-03-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド プロテインａクロマトグラフィー－エレクトロスプレーイオン化質量分析計
BR112021014427A2 (pt) 2019-01-25 2021-09-28 Regeneron Pharmaceuticals, Inc. Quantificação e identificação de dímeros em coformulações
EP3923978A1 (en) 2019-02-12 2021-12-22 Regeneron Pharmaceuticals, Inc. Compositions and methods for using bispecific antibodies to bind complement and a target antigen
CA3128519A1 (en) 2019-02-21 2020-08-27 Regeneron Pharmaceuticals, Inc. Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
CN113677707A (zh) 2019-03-06 2021-11-19 瑞泽恩制药公司 用于在治疗癌症中增强效力的il-4/il-13途径抑制剂
CN114144672A (zh) 2019-04-17 2022-03-04 瑞泽恩制药公司 宿主细胞蛋白质的鉴定
US10961500B1 (en) 2019-04-23 2021-03-30 Regeneron Pharmaceuticals, Inc. Cell culture medium for eukaryotic cells
TW202106699A (zh) 2019-04-26 2021-02-16 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
SG11202111262XA (en) 2019-05-13 2021-11-29 Regeneron Pharma Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
JP2022532503A (ja) 2019-05-13 2022-07-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された競合的リガンド結合アッセイ
AU2020294790A1 (en) 2019-06-21 2021-12-16 Regeneron Pharmaceuticals, Inc. Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation
WO2020257681A1 (en) 2019-06-21 2020-12-24 Regeneron Pharmaceuticals, Inc. Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
CA3146933A1 (en) 2019-09-16 2021-03-25 Marcus KELLY Radiolabeled met binding proteins for immuno-pet imaging
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
AU2020352547A1 (en) 2019-09-24 2022-03-31 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
IL293131A (en) 2019-11-25 2022-07-01 Univ California Long-acting vegf inhibitors for intraocular neovascularization
MX2022006236A (es) 2019-11-25 2022-06-22 Regeneron Pharma Formulaciones de liberacion sostenida con emulsiones no acuosas.
MY193351A (en) 2019-12-06 2022-10-06 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
US20230063116A1 (en) * 2019-12-06 2023-03-02 Regeneron Pharmaceuticals, Inc. Vegf mini-traps and method of use thereof
WO2021123908A1 (en) 2019-12-20 2021-06-24 Ludwig Institute For Cancer Research Ltd Car-t cell therapy targeting ngcgm3
EP4085253B1 (en) 2020-01-21 2024-03-13 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins
BR112022014461A2 (pt) 2020-01-24 2022-09-13 Regeneron Pharma Antígeno preferencialmente expresso em receptores de células t de melanoma (prame) e métodos de uso dos mesmos
MX2022010654A (es) 2020-02-27 2022-11-16 Regeneron Pharma Metodos para reducir la degradacion de polisorbato en formulaciones farmacologicas.
AU2021228225A1 (en) 2020-02-28 2022-09-01 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind HER2, and methods of use thereof
BR112022017156A2 (pt) 2020-03-06 2022-11-08 Regeneron Pharma Anticorpo isolado ou fragmento de ligação, molécula polinucleotídica isolada, vetor, célula hospedeira isolada, composição farmacêutica, método de tratamento de câncer, e, uso de um anticorpo
IL296787A (en) 2020-03-30 2022-11-01 Regeneron Pharma Methods for protein characterization of low proliferative host cells
US20210347852A1 (en) * 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
CN115734971A (zh) 2020-06-22 2023-03-03 信达生物制药(苏州)有限公司 抗ang-2抗体及其用途
CN118085100A (zh) 2020-07-13 2024-05-28 瑞泽恩制药公司 与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途
CA3189206A1 (en) 2020-07-16 2022-01-20 Raqualia Pharma Inc. Trpv4 inhibitor as therapeutic agent for ocular disease
MX2023000547A (es) 2020-07-16 2023-02-13 Novartis Ag Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas.
TW202225398A (zh) 2020-08-31 2022-07-01 美商再生元醫藥公司 用以改良細胞培養效能及減少天冬醯胺序列變異之天冬醯胺饋料策略
US20230374160A1 (en) 2020-10-02 2023-11-23 Regeneron Pharmaceuticals, Inc. Combination of antibodies for treating cancer with reduced cytokine release syndrome
CA3190569A1 (en) 2020-10-22 2022-04-28 Christopher Daly Anti-fgfr2 antibodies and methods of use thereof
MX2023004935A (es) 2020-11-10 2023-07-07 Regeneron Pharma Conjugados de anticuerpos y selenio.
IL303027A (en) 2020-11-25 2023-07-01 Regeneron Pharma Sustained release formulations by creating a non-aqueous membrane emulsion
EP4262757A1 (en) 2020-12-17 2023-10-25 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
MX2023008527A (es) 2021-01-20 2023-07-28 Regeneron Pharma Metodos para mejorar el valor proteico en cultivo celular.
KR20230135627A (ko) 2021-01-25 2023-09-25 리제너론 파아마슈티컬스, 인크. 항-PDGF-b 항체 및 폐동맥 고혈압 (PAH)을 치료하기 위한 사용 방법
CA3206253A1 (en) 2021-02-04 2022-08-11 Heung Rok Park Anti-pd-1 antibody and use thereof
JP2024507144A (ja) 2021-02-11 2024-02-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ネオアジュバントｐｄ－１阻害剤を投与することによってがんを処置する方法
WO2022182632A1 (en) 2021-02-23 2022-09-01 Regeneron Pharmaceuticals, Inc. Methods of treating lung cancer by administering a pd-1 inhibitor
AU2022230987A1 (en) 2021-03-03 2023-08-31 Regeneron Pharmaceuticals, Inc. Systems and methods for quantifying and modifying protein viscosity
JP2024511106A (ja) 2021-03-23 2024-03-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｐｄ－１阻害剤を投与することにより免疫抑制または免疫不全患者におけるがんを処置する方法
EP4315344A1 (en) 2021-03-26 2024-02-07 Regeneron Pharmaceuticals, Inc. Methods and systems for developing mixing protocols
TW202313096A (zh) 2021-05-28 2023-04-01 大陸商江蘇恆瑞醫藥股份有限公司 衣殼變異的重組腺相關病毒及其應用
EP4348234A1 (en) 2021-06-01 2024-04-10 Regeneron Pharmaceuticals, Inc. Micropchip capillary electrophoresis assays and reagents
CA3212850A1 (en) 2021-06-22 2022-12-29 Frank DELFINO Anti-egfrviii antibody drug conjugates and uses thereof
KR20240031400A (ko) 2021-07-13 2024-03-07 리제너론 파아마슈티컬스, 인크. 음이온-교환 크로마토그래피 질량분광분석 (aex-ms)에 의한 단백질의 특성화
WO2023287823A1 (en) 2021-07-13 2023-01-19 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based strategy for determining product-related variants of a biologic
TW202326138A (zh) 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
US20230084196A1 (en) 2021-09-14 2023-03-16 Regeneron Pharmaceuticals, Inc. Nmass spectrometry-based strategy for characterizing high molecular weight species of a biologic
AU2022354864A1 (en) 2021-09-28 2024-03-07 Regeneron Pharmaceuticals, Inc. Assays to quantitate drug and target concentrations
CN118076885A (zh) 2021-10-07 2024-05-24 里珍纳龙药品有限公司 pH计校准与校正
TW202323817A (zh) 2021-10-07 2023-06-16 美商再生元醫藥公司 Ｐｈ建模及控制之系統及方法
WO2023076340A1 (en) 2021-10-26 2023-05-04 Regeneron Pharmaceuticals, Inc. Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
IL312405A (en) 2021-11-01 2024-06-01 Regeneron Pharma Methods to prevent disulfide scrambling for mass spectroscopy-based proteomics
US20230192886A1 (en) 2021-11-08 2023-06-22 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
US20230235089A1 (en) 2021-11-24 2023-07-27 Regeneron Pharmaceuticals, Inc. Methods for Treating Cancer with Bispecific Anti-CD3 x MUC16 Antibodies and Anti-CTLA-4 Antibodies
TW202346320A (zh) 2021-12-01 2023-12-01 美商凱德蒙有限責任公司 Ｂ７－ｈ４抗體和抗ｂ７－ｈ４抗體／ｉｌ－１５融合蛋白
US20230287138A1 (en) 2022-01-12 2023-09-14 Regneron Pharmaceuticals, Inc. Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
US20230296559A1 (en) 2022-03-18 2023-09-21 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
WO2023196903A1 (en) 2022-04-06 2023-10-12 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
US20240148867A1 (en) 2022-10-31 2024-05-09 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a combination of adoptive cell therapy and a targeted immunocytokine
WO2024118785A2 (en) 2022-11-30 2024-06-06 Regeneron Pharmaceuticals, Inc. Tlr7 agonists and antibody-drug-conjugates thereof
US20240198253A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5663304A (en) 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
DE69633175T2 (de) * 1995-05-23 2005-08-11 Morphosys Ag Multimere proteine
JPH09154588A (ja) * 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
AU2650597A (en) * 1996-05-02 1997-11-26 Mochida Pharmaceutical Co., Ltd. Novel fas antigen derivatives
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6423512B1 (en) 1996-07-26 2002-07-23 Novartis Ag Fusion polypeptides
CA2266419A1 (en) 1996-09-24 1998-04-02 Merck & Co., Inc. Gene therapy for inhibition of angiogenesis
ES2273497T3 (es) 1998-06-15 2007-05-01 Gtc Biotherapeutics, Inc. Proteina de fusion de la albumina serica humana de eritropoyetina analoga.
EA003922B1 (ru) 1999-05-17 2003-10-30 Конджачем, Инк. Продолжительно действующие инсулинотропные пептиды
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
UA74146C2 (ru) * 1999-06-08 2005-11-15 Редженерон Фармасьютікалс, Інк. Модицированный химерический полипептид с улучшенными фармакокинетическими свойствами

Also Published As

Publication number Publication date
US20050043236A1 (en) 2005-02-24
AR044938A1 (es) 2005-10-12
DK1947118T3 (da) 2011-02-07
AU2004252175A1 (en) 2005-01-06
TWI330197B (en) 2010-09-11
US20090062200A1 (en) 2009-03-05
SI1947118T1 (sl) 2011-02-28
CN1816566B (zh) 2011-01-12
HK1082511A1 (en) 2006-06-09
JP2007528708A (ja) 2007-10-18
NZ572107A (en) 2009-01-31
WO2005000895A2 (en) 2005-01-06
IL172404A0 (en) 2006-04-10
EP1947118A1 (en) 2008-07-23
CA2529660A1 (en) 2005-01-06
DE602004020474D1 (de) 2009-05-20
IL204984A (en) 2011-12-29
US20100087632A1 (en) 2010-04-08
PL1639007T3 (pl) 2009-11-30
KR20060096184A (ko) 2006-09-08
CA2529660C (en) 2013-08-06
RU2376373C2 (ru) 2009-12-20
NZ544569A (en) 2008-12-24
JP2010246557A (ja) 2010-11-04
US20040014667A1 (en) 2004-01-22
UA105625C2 (ru) 2014-06-10
EP1639007B1 (en) 2009-04-08
IL172404A (en) 2011-12-29
MY154826A (en) 2015-07-31
CY1111605T1 (el) 2015-10-07
CN1816566A (zh) 2006-08-09
ZA200600157B (en) 2007-04-25
SI1639007T1 (sl) 2009-08-31
PT1947118E (pt) 2010-12-02
US7279159B2 (en) 2007-10-09
PL1947118T3 (pl) 2011-05-31
RU2006102497A (ru) 2006-06-10
ATE486091T1 (de) 2010-11-15
ES2354847T3 (es) 2011-03-18
US7635474B2 (en) 2009-12-22
PT1639007E (pt) 2009-06-04
ATE427962T1 (de) 2009-04-15
TW200513532A (en) 2005-04-16
UY28396A1 (es) 2004-11-08
US7087411B2 (en) 2006-08-08
ES2323468T3 (es) 2009-07-16
NO20060483L (no) 2006-03-28
EP1639007A2 (en) 2006-03-29
MXPA05013641A (es) 2006-02-24
DE602004029833D1 (de) 2010-12-09
AU2004252175B2 (en) 2010-07-22
WO2005000895A3 (en) 2005-09-15
NO339766B1 (no) 2017-01-30
CY1109204T1 (el) 2014-07-02
DK1639007T3 (da) 2009-06-08
EP1947118B1 (en) 2010-10-27
KR101131429B1 (ko) 2012-07-27
US7972598B2 (en) 2011-07-05
BRPI0412125A (pt) 2006-08-15

Similar Documents

Publication Publication Date Title
UA90657C2 (ru) Ловушки vegf и их терапевтические применения
MXPA05010830A (es) Metodos de tratamiento que usan agentes de enlace especificos de angiopoyetina-2 humana.
CA2523467C (en) Treatment of t-cell mediated diseases
WO2007091250A8 (en) Enzyme replacement therapy for treating lysosomal storage diseases
DE60028970D1 (de) An her2 bindende peptidverbindungen
DE602004031390D1 (de) Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten
ATE418346T1 (de) Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen
DK1799235T3 (da) Sammensætninger af fosterhudcelleprotein til behandling af hudtilstande, -lidelser eller -sygdomme og fremgangsmåder til fremstilling og anvendelse deraf
AU2002305450A1 (en) Proteomimetic compounds and methods
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
ATE406170T1 (de) Kontrolle des proteinspiegels in eukaryotischen organismen
WO2010065077A3 (en) Antagonists of il-6 to prevent or treat thrombosis
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
EA200600735A1 (ru) Нуклеиновые кислоты, специфично связывающие биоактивный грелин
DK2229440T3 (da) Rekombinante elastase-proteiner og fremgangsmåder til fremstilling og anvendelse deraf
WO2006047728A3 (en) Bmp gene and fusion protein
WO2005089123A3 (en) Therapeutic anti-cancer dna
WO2003076610A3 (fr) Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations
PL1636261T3 (pl) Białka trombopoetynowe o ulepszonych właściwościach
WO2005094236A3 (en) Activation of hypoxia-inducible gene expression
EA200700346A1 (ru) Бактериофаг- и профаг-специфические протеины в генной терапии рака
WO2006138610A3 (en) Interferon-alpha/beta binding fusion proteins and therapeutic uses thereof
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
WO2004113386A3 (en) Modified hirudin proteins and t-cell epitopes in hirudin
TW200716749A (en) Interferon-beta gene therapy using an improved, regulated expression system